What causes prostate cancer?

Written by Zhou Zi Hua
Oncology
Updated on September 22, 2024
00:00
00:00

The current causes of prostate cancer are not completely understood, but a large amount of research indicates that genetic and environmental factors play a significant role. Dietary factors, such as the intake of a large amount of unsaturated fatty acids, vasectomy, smoking, obesity, and alcohol consumption, also increase the risk of developing prostate cancer. Overall, the occurrence and development of prostate cancer are related to various factors, including both internal causes in the patient and the influence of external factors.

Other Voices

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
27sec home-news-image

Late-stage prostate cancer with bone metastases: how long can one survive?

Bone metastasis is the most common site of metastasis for prostate cancer. If prostate cancer has metastasized to the bones, it means it is not in its early stages but has entered the advanced stages. However, this type of tumor is not like others with a higher degree of malignancy. If it has a good sensitivity to hormone therapy, after our standardized treatment, the survival time can still be quite long.

doctor image
home-news-image
Written by Liu Liang
Oncology
43sec home-news-image

Typical symptoms of prostate cancer

Early-stage prostate patients often do not exhibit significant clinical symptoms. However, when the prostate cancer tumor invades the surrounding tissues and structures, it can cause corresponding clinical manifestations such as urinary tract irritation and urinary obstruction. Symptoms include difficulty urinating or frequent urination, painful urination, and even urinary incontinence, perineal pain, and sciatica. Bone metastasis is a common site of metastasis in prostate cancer patients, causing pain in the affected area and even pathological fractures.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
49sec home-news-image

Prostate cancer radiotherapy is conducted in what way?

Indications for radiation therapy for prostate cancer include clinical stages T1 to T4, M0 to M1. M0-stage prostate cancer patients undergo radiation therapy techniques including external beam radiation and brachytherapy. External beam radiation techniques comprise conventional radiation therapy, three-dimensional conformal radiation therapy, and intensity-modulated radiation therapy. Permanent seed implantation is used only for the treatment of early-stage localized prostate cancer with a good prognosis. External radiation therapy is divided into three categories based on therapeutic objectives: curative, adjuvant, and palliative radiation therapy.

doctor image
home-news-image
Written by Liu Liang
Oncology
45sec home-news-image

Can prostate cancer be detected by ultrasound B?

Prostate cancer can generally be detected through ultrasound, as it reveals nodules in the prostate. By examining the internal echoes of these nodules, one can differentiate between benign and malignant prostate conditions. Thus, in foreign countries, ultrasound, specifically prostate color Doppler ultrasound examinations, are used as a screening method for prostate cancer. In China, screening methods also include traditional digital rectal examinations and generally involve blood tests for specific prostate tumor markers, namely PSA. These tests are combined with prostate ultrasound for a comprehensive assessment.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
40sec home-news-image

androgen deprivation therapy for prostate cancer

Androgen deprivation therapy for prostate cancer includes surgical castration, which can quickly and continuously reduce levels to very low levels. The second is medical castration, which involves the use of analogs of luteinizing hormone-releasing hormone. Currently available products include leuprolide, goserelin, and triptorelin. Third, estrogen therapy, with diethylstilbestrol being the most common estrogen treatment. Surgical castration, medical castration, or estrogen therapy offer similar progression-free survival rates in patients with tumor-related outcomes.